fda semaglutide bulk exclusion
Facing Loss, Clinics Grapple With Semaglutide Exclusion
In 2026, the FDA announced plans to exclude three GLP-1 drugs - semaglutide, tirzepatide and liraglutide - from the 503B bulk list, aiming to curb unauthorized compounding of weight-loss medications. This regulatory shift could raise costs for patients and reshape the supply chain for obesity treatments across the United States.
